Robust IPO activity in late 2026 reflects favorable equity market conditions, with 267 U.S. deals completed year-to-date through mid-November and multiple offerings priced in recent weeks, including vVARDIS Holding and Windward Bio Group. Primary drivers include strong investor demand for AI and biotech names, supportive valuations, and a pipeline of large filings such as Anthropic’s S-1, which set terms for a potential November 19 pricing targeting tens of billions in proceeds. Recent data show continued filings and roadshows through December, alongside SPAC activity, indicating sustained issuance momentum before year-end. Key upcoming catalysts include additional pricing windows in the final six weeks of 2026 and any shifts in Treasury yields or equity volatility that could affect underwriting calendars.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено1H6H1D7D30DALL
View resolved





























Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы